Journal
CLINICAL CANCER RESEARCH
Volume 18, Issue 7, Pages 1824-1826Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-12-0151
Keywords
-
Categories
Funding
- NIDDK NIH HHS [R01 DK076986, R01 DK076986-05] Funding Source: Medline
- ICREA Funding Source: Custom
Ask authors/readers for more resources
Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting. Clin Cancer Res; 18(7); 1824-6. (C) 2012 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
